HCC patients in the low-risk group were associated with intensified metabolic pathways related to anti-inflammation and anti-tumorigenesis, including arachidonic acid metabolism, drug metabolism, PPAR signaling pathway, fatty acid metabolism, xenobiotics metabolism and tryptophan metabolism, providing new evidence for supporting that the four DElncRNAs could serve as an efficient biomarker for HCC. Here, PPARA is linked to hepatocellular carcinoma.